Inflammatory bowel diseases are characterized by a dysfunctional intestinal immune system,
associated with the imbalanced upregulation of helper T cells (Th), leukocyte trafficking …

Summary Background In the IMAgINE 1 study, adalimumab induced and maintained
remission of moderate‐to‐severe Crohn's disease in children. Aim To assess the efficacy …

Background: Interferon-γ release assay (IGRA) is widely used for screening of latent
tuberculosis (TB) before and during biological therapy (BT). An indeterminate result of IGRA …

Abstract Background and Aim: Adalimumab is well-established therapy for adults with
Crohn's disease [CD]. The aim of the study was to systematically assess the published …

Background Pivotal trials for adalimumab (ADA) demonstrated effectiveness versus placebo
for induction and maintenance of remission in moderate to severely active Crohn's disease …

Biological therapies, especially blocking tumor necrosis factor-α (TNFα) agents have
radically changed the therapeutic approach and disease course of pediatric inflammatory …

The efficacy and safety of biologic response modifiers such as etanercept, adalimumab,
infliximab, and ustekinumab have been demonstrated in the treatment of psoriasis in adults …

The use of biologic agents in pediatric inflammatory bowel d... : Current Opinion in Pediatrics
The use of biologic agents in pediatric inflammatory bowel disease : Current Opinion in …

Anti–tumor necrosis factor agents are now considered to be a vital component of the
treatment algorithm for pediatric inflammatory bowel disease. Despite the clear benefit of …

Introduction Children and adolescents with Crohn's disease present unique challenges due
to extensive disease at diagnosis and the effect of bowel inflammation on growth. Historical …